Worth Asset Management’s Pfizer PFE Stock Holding History

Worth Asset Management’s Portfolio PFE Stock Details PFE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-550	Closed	-$20.2K	–	321
2023 Q2	$20.2K	Buy	550 +25	+5%	+$973	0.02%	244
2023 Q1	$21.4K	Hold	525	–	–	0.02%	260
2022 Q4	$26.9K	Hold	525	–	–	0.02%	238
2022 Q3	$23K	Hold	525	–	–	0.02%	212
2022 Q2	$28K	Sell	525 -56	-10%	-$2.85K	0.02%	261
2022 Q1	$29K	Buy	+581	New	+$30.1K	0.02%	267

Other funds holding PFE

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Worth Asset Management's PFE Position: Q3 2023 in Review

Worth Asset Management sold out of Pfizer (PFE) in Q3 2023, closing a stake of 550 shares — an estimated $20.2K sold.

Worth Asset Management first reported a position in PFE in Q1 2022 and held it in 6 quarters. The position peaked at $29K in Q1 2022. 2,926 funds tracked by Wall St. Rank hold PFE as of Q3 2023.

Worth Asset Management reported no remaining Pfizer position as of Q3 2023 after selling out during the quarter.
Worth Asset Management sold 550 Pfizer shares in Q3 2023, an estimated $20.2K.
Worth Asset Management first reported a position in Pfizer in Q1 2022 and held it in 6 quarters.
Worth Asset Management's Pfizer position peaked at $29K in Q1 2022.
2,926 funds tracked by Wall St. Rank held Pfizer as of Q3 2023.

Based on Worth Asset Management's 13F filing for Q3 2023, filed 11 Oct 2023.